Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson’s disease

Berti, Valentina; Polito, Cristina; Ramat, Silvia; Vanzi, E.; Cristofaro, Maria Teresa De; Pellicanò, Giannantonio; Mungai, Francesco; Marini, P.; Formiconi, Andreas Robert; Sorbi, Sandro; Pupi, Alberto

doi:10.1007/s00259-009-1259-x

Cited by 37 publications

(30 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous research has found associations of occipital reduction with visuospatial deficits 10 30. However, the occipital pole hypometabolism is similar in PD with dementia to cognitively normal PD,10 31 and does not seem related to the severity of motor features 32 33. Occipital hypoperfusion/metabolism is also a distinctive feature of DLB,34 in which it does not vary with severity of parkinsonism 35.…”

Section: Discussionmentioning

confidence: 92%

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study

Firbank

Yarnall

Lawson

et al. 2016

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

Objective To assess reductions of cerebral glucose metabolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), and their associations with cognitive decline. Methods FDG-PET was performed on a cohort of 79 patients with newly diagnosed PD (mean disease duration 8 months) and 20 unrelated controls. PD participants were scanned while on their usual dopaminergic medication. Cognitive testing was performed at baseline, and after 18 months using the Cognitive Drug Research (CDR) and Cambridge Neuropsychological Test Automated Battery (CANTAB) computerised batteries, the Mini-Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA). We used statistical parametric mapping (SPM V.12) software to compare groups and investigate voxelwise correlations between FDG metabolism and cognitive score at baseline. Linear regression was used to evaluate how levels of cortical FDG metabolism were predictive of subsequent cognitive decline rated with the MMSE and MoCA. Results PD participants showed reduced glucose metabolism in the occipital and inferior parietal lobes relative to controls. Low performance on memory-based tasks was associated with reduced FDG metabolism in posterior parietal and temporal regions, while attentional performance was associated with more frontal deficits. Baseline parietal to cerebellum FDG metabolism ratios predicted MMSE (β=0.38, p=0.001) and MoCA (β=0.3, p=0.002) at 18 months controlling for baseline score. Conclusions Reductions in cortical FDG metabolism were present in newly diagnosed PD, and correlated with performance on neuropsychological tests. A reduced baseline parietal metabolism is associated with risk of cognitive decline and may represent a potential biomarker for this state and the development of PD dementia.

show abstract

Section: Discussionmentioning

confidence: 92%

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study

Firbank

Yarnall

Lawson

et al. 2016

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

show abstract

“…While hypometabolism is limited in the frontal and occipital cortices of PD patients with no cognitive impairment [18] , it becomes more widespread within cortical regions in advanced PD [14] . Further, the relationships of abnormal rCMRglc with clinical symptoms and impaired striatal DAT binding have been examined in de novo untreated PD patients [19] . Correlation analyses showed that the UPDRS motor ratings were negatively correlated with rCMRglc in the premotor cortex (PMC), while putaminal DAT binding was positively correlated with rCMRglc in the premotor, dorsolateral prefrontal, anterior prefrontal, and orbitofrontal cortices.…”

Section: Functional Brain Imaging: Univariate Analysesmentioning

confidence: 99%

Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson’s disease

Peng

Eidelberg

2014

Neurosci. Bull.

View full text Add to dashboard Cite

Neuroimaging of cerebral glucose metabolism and blood flow is ideally suited to assay widely-distributed brain circuits as a result of local molecular events and behavioral modulation in the central nervous system. With the progress in novel analytical methodology, this endeavor has succeeded in unraveling the mechanisms underlying a wide spectrum of neurodegenerative diseases. In particular, statistical brain mapping studies have made significant strides in describing the pathophysiology of Parkinson’s disease (PD) and related disorders by providing signature biomarkers to determine the systemic abnormalities in brain function and evaluate disease progression, therapeutic responses, and clinical correlates in patients. In this article, we review the relevant clinical applications in patients in relation to healthy volunteers with a focus on the generation of unique spatial covariance patterns associated with the motor and cognitive symptoms underlying PD. These characteristic biomarkers can be potentially used not only to improve patient recruitment but also to predict outcomes in clinical trials.

show abstract

“…Motor dysfunction in PD is generally better understood than the nonmotor aspects of this disorder, with blood flow and metabolic alterations in the basal ganglia and premotor cortex correlating with motor dysfunction in PD [22,23,24]. FDG-PET studies examining cognitive dysfunction have revealed frontal, temporoparietal association cortex, and occipital metabolic reductions in PD with mild cognitive impairment versus PD subjects without cognitive impairment [25,26].…”

Section: Introductionmentioning

confidence: 99%

Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Computed Tomography Study

Huang¹,

Ravdin²,

Nirenberg³

et al. 2013

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Aim: We sought to identify markers of motor and nonmotor function in Parkinson's disease (PD) using advanced neuroimaging techniques in subjects with PD. Methods: We enrolled 26 nondemented PD subjects and 12 control subjects. All subjects underwent [¹⁸F]fluorodeoxyglucose positron emission computed tomography (FDG-PET) and magnetic resonance imaging, and a complete neuropsychological battery. Results: FDG-PET of subjects with PD revealed significant metabolic elevations in the bilateral posterior lentiform nucleus, posterior cingulate, and parahippocampus, and metabolic reductions in the bilateral temporoparietal association cortex and occipital lobe versus controls. PD subjects had significant reductions in executive/attention function, memory/verbal learning, and speed of thinking, and significantly increased depression, anxiety and apathy scores compared with controls. Motor dysfunction correlated with increased metabolism in the posterior lentiform nucleus, pons, and cerebellum, and decreased metabolism in the temporoparietal lobe. Cognitive dysfunction correlated with increased posterior cingulate metabolism and decreased temporoparietal lobe metabolism. Depressive symptoms correlated with increased amygdala metabolism; anxiety scores correlated with decreased caudate metabolism, and apathy scores correlated with increased metabolism in the anterior cingulate and orbitofrontal lobe and decreased metabolism in the temporoparietal association cortex. Conclusions: Our findings showed that motor, cognitive, and emotional dysfunction in PD are associated with distinct patterns of cerebral metabolic changes.

show abstract

Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson’s disease

Cited by 37 publications

References 45 publications

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study

Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson’s disease

Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Computed Tomography Study

Contact Info

Product

Resources

About